SRZN
Surrozen, Inc./DE
$20.69
-3.86%
$240.2M
No data for this timeframe.
Vol
Market Cap$240.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders4 funds
Inst. Value$9.2M
Inst. Activity2 buys / 0 sells
Insider Activity10B / 3S
Insider Net $$2.2M
SEC Reports2
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001824893·Prev Close $21.52
Recent Activity
May 13, 2026
Insider
WOODHOUSE DAVID J sold 5,550 shares
Director @ $0.00 ($0.00)
May 13, 2026
Insider
Berkenblit Anna sold 5,550 shares
Director @ $0.00 ($0.00)
May 13, 2026
Insider
BJERKHOLT ERIC sold 5,550 shares
Director @ $0.00 ($0.00)
May 12, 2026
other
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference
May 5, 2026
SEC
CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val
CLUSTER — Impact 2/10
Mar 23, 2026
SEC
Surrozen, Inc. has filed an S-3 shelf registration statement with the SEC, authorizing the potential issuance of up to $
S-3 — Impact 7/10
Inst.
BANK OF AMERICA CORP — DOUBLED
29,608 shares ($669.1K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
22,626 shares ($511.3K)
Price Targets
$42.50
+97.7% upside
Strong Buy
Current $21.50
Low $40.00
Median $43.00
High $44.00
4 analysts
$40.00
$44.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | TD Cowen | INITIATE | Buy |
| Mar 24, 2026 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 19, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.26 ▼ -13.5% | $-1.28 — $-1.24 | -11% YoY | 2 |
| Next Q | $-1.29 ▼ -13.1% | $-1.40 — $-1.19 | 64% YoY | 2 |
| Current FY | $-3.70 | $-3.70 — $-3.70 | 1 | |
| Next FY | $-3.98 ▼ -11.8% | $-4.46 — $-3.51 | -8% YoY | 2 |
Latest Reports
NEUTRAL
CLUSTER
2/10
CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val
May 5, 2026
BEARISH
S-3
7/10
Surrozen, Inc. has filed an S-3 shelf registration statement with the SEC, authorizing the potential issuance of up to $
Mar 23, 2026
MIXED
Press
6/10
Surrozen reported its 2025 financial results, showing a significant increase in net loss to $242.0 million due to non-ca
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $7.2M | DOUBLED |
| MORGAN STANLEY | $835.3K | — |
| BANK OF AMERICA CORP | $669.1K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $511.3K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 13, 2026 | WOODHOUSE DAVID | A | $0.00 |
| May 13, 2026 | Berkenblit Anna | A | $0.00 |
| May 13, 2026 | BJERKHOLT ERIC | A | $0.00 |
| May 13, 2026 | CHAI CHRISTOPHER | A | $0.00 |
| May 13, 2026 | Haak-Frendscho Mary | A | $0.00 |
4 institutional holders with $9.2M total value (408,431 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 319,236 | $7.2M | 78.2% | DOUBLED +221.9% |
| 2 | MORGAN STANLEY | 36,961 | $835.3K | 9.0% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 29,608 | $669.1K | 7.2% | DOUBLED +493366.7% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 22,626 | $511.3K | 5.5% | ADD +53.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 6 | 29,608 | +493366.7% | $669.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 14,726 | 22,626 | +53.6% | $511.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 52 | 6 | -88.5% | $77.00 | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 68,026 | 218,950 | +221.9% | $2.0M | 2025-Q2 |
| UBS Group AG | ADD | 197 | 259 | +31.5% | $2.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 16 | 52 | +225.0% | $465.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 32 | 197 | +515.6% | $2.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 10,930 | 0 | -100.0% | $0.00 | 2024-Q4 |
11 unique insiders with 13 transactions. Net insider value: $2.2M ($2.4M bought, $271.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 13, 2026 | WOODHOUSE DAVID J | Director | A | 5,550 | $0.00 | $0.00 |
| May 13, 2026 | Berkenblit Anna | Director | A | 5,550 | $0.00 | $0.00 |
| May 13, 2026 | BJERKHOLT ERIC | Director | A | 5,550 | $0.00 | $0.00 |
| May 13, 2026 | CHAI CHRISTOPHER Y | Director | A | 5,550 | $0.00 | $0.00 |
| May 13, 2026 | Haak-Frendscho Mary | Director | A | 5,550 | $0.00 | $0.00 |
| May 13, 2026 | Rothenberg Mace | Director | A | 5,550 | $0.00 | $0.00 |
| May 13, 2026 | Kutzkey Tim | Director | A | 5,550 | $0.00 | $0.00 |
| May 4, 2026 | Li Yang | Exec. Vice President, Research | SELL | 1,584 | $33.33 | $52.8K |
| May 4, 2026 | Williams Charles O | Chief Operating Officer | SELL | 2,036 | $33.33 | $67.9K |
| May 4, 2026 | Parker Craig C | Chief Executive Officer | SELL | 4,524 | $33.33 | $150.8K |
| May 1, 2026 | Li Yang | Exec. Vice President, Research | M | 4,375 | $0.00 | $0.00 |
| May 1, 2026 | Li Yang | Exec. Vice President, Research | M | 4,375 | $0.00 | $0.00 |
| May 1, 2026 | Williams Charles O | Chief Operating Officer | M | 5,625 | $0.00 | $0.00 |
| May 1, 2026 | Williams Charles O | Chief Operating Officer | M | 5,625 | $0.00 | $0.00 |
| May 1, 2026 | Parker Craig C | Chief Executive Officer | M | 12,500 | $0.00 | $0.00 |
| May 1, 2026 | Parker Craig C | Chief Executive Officer | M | 12,500 | $0.00 | $0.00 |
| Mar 31, 2026 | Li Yang | Exec. Vice President, Research | G | 1,666 | $0.00 | $0.00 |
| Mar 24, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 53,329 | $24.69 | $1.3M |
| Mar 23, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 7,612 | $24.90 | $189.5K |
| Mar 16, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 595 | $24.99 | $14.9K |
| Mar 13, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 17,717 | $24.88 | $440.7K |
| Mar 12, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 6,187 | $24.99 | $154.6K |
| Feb 12, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 547 | $23.86 | $13.1K |
| Feb 11, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 8,882 | $23.58 | $209.4K |
| Feb 3, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 2,178 | $21.94 | $47.8K |
| Feb 2, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 366 | $21.38 | $7.8K |
| Jan 30, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | BUY | 2,136 | $21.39 | $45.7K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 4.5/10.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.50 mean target
+97.7% upside
Strong Buy (3.00)
$40.00 Low
$44.00 High
| Metric | Value |
|---|---|
| Current Price | $21.50 |
| Target Low | $40.00 |
| Target Mean | $42.50 |
| Target Median | $43.00 |
| Target High | $44.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.26 | $-1.28 | $-1.24 | -10.8% | -13.5% | 0↑ 2↓ | $0.0B | -11.6% | 2 |
| Next Q 2026-09-30 |
$-1.29 | $-1.40 | $-1.19 | 64.1% | -13.1% | 0↑ 2↓ | $0.0B | -11.6% | 2 |
| Current FY 2026-12-31 |
$-3.70 | $-3.70 | $-3.70 | — | +0.0% | — | $0.0B | 68.8% | 1 |
| Next FY 2027-12-31 |
$-3.98 | $-4.46 | $-3.51 | -7.7% | -11.8% | 0↑ 2↓ | $0.0B | -40.8% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.260 | |
| 7d ago | $-1.110 | -0.150 |
| 30d ago | $-1.110 | -0.150 |
| 60d ago | $-1.360 | +0.100 |
| 90d ago | $-1.170 | -0.090 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 24, 2026 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 19, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
other
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference
May 8, 2026
earnings_calendar
SRZN Q1 2026 Earnings Scheduled — 2026-05-08
Mar 30, 2026
earnings_calendar
SRZN Q4 2025 Earnings After Market Close — 2026-03-30
Mar 23, 2026
earnings
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update